Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics PLC (SMMT)
:SMMT
Holding SMMT?
Track your performance easily
SMMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $33.89
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.16M
Market Cap
$13.16B
Enterprise Value$15.46B
Total Cash (Recent Filing)$11.27M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Mar 13, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding737,448,100
10 Day Avg. Volume2,130,678
30 Day Avg. Volume2,155,337
Standard Deviation0.63
R-Squared0.00534
Alpha0.13
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-108.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-102.40
Forecast
1Y Price Target
$35.33Price Target Upside94.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Summit Therapeutics News
PremiumCompany Announcements
Summit Therapeutics Highlights Success at Healthcare Conference
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyIvonescimab's data complement the competitor BNT327, suggesting that near-term newsflow should prove positive for both companies.
Market OpportunitySMMT is a front-runner in grabbing a big chunk of the $100B opportunity in the PD1/VEGF space.
Regulatory AdvancementsThe FDA granted ivonescimab Fast Track designation, which expedites regulatory interactions and allows for rolling review of Biologic License Applications.
Bears Say
Data ReliabilityThe data are uncontrolled and with very limited N, thus a 25% PoS and 30% peak market share is the most optimistic realistic assessment of these opportunities.
Geographic LimitationsAll data so far are from China, raising concerns about broader applicability.
Market OutlookExpected share price return 0.8%.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SMMT FAQ
What was Summit Therapeutics PLC’s price range in the past 12 months?
Summit Therapeutics PLC lowest stock price was $2.10 and its highest was $33.89 in the past 12 months.
What is Summit Therapeutics PLC’s market cap?
Summit Therapeutics PLC’s market cap is $13.16B.
When is Summit Therapeutics PLC’s upcoming earnings report date?
Summit Therapeutics PLC’s upcoming earnings report date is Mar 13, 2025 which is in 58 days.
How were Summit Therapeutics PLC’s earnings last quarter?
Summit Therapeutics PLC released its earnings results on Oct 30, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.017.
Is Summit Therapeutics PLC overvalued?
According to Wall Street analysts Summit Therapeutics PLC’s price is currently Undervalued.
Does Summit Therapeutics PLC pay dividends?
Summit Therapeutics PLC does not currently pay dividends.
What is Summit Therapeutics PLC’s EPS estimate?
Summit Therapeutics PLC’s EPS estimate is -0.08.
How many shares outstanding does Summit Therapeutics PLC have?
Summit Therapeutics PLC has 737,448,100 shares outstanding.
What happened to Summit Therapeutics PLC’s price movement after its last earnings report?
Summit Therapeutics PLC reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went down -14.567%.
Which hedge fund is a major shareholder of Summit Therapeutics PLC?
Among the largest hedge funds holding Summit Therapeutics PLC’s share is Baker Bros Advisors LP. It holds Summit Therapeutics PLC’s shares valued at 535M.
---
Summit Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.33 (94.33% Upside)
$35.33 (94.33% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
486.29%
12-Months-Change
Fundamentals
Return on Equity
-73.22%
Trailing 12-Months
Asset Growth
130.16%
Trailing 12-Months
Company Description
Summit Therapeutics PLC
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
---
SMMT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Summit Therapeutics demonstrated strong progress and expansion in their clinical trials for ivonescimab, supported by substantial fundraising and strategic partnerships. However, increased operating expenses and uncertainties regarding the overall survival outcomes from current trials present notable challenges.Read More>---
SMMT Stock 12 Month Forecast
Average Price Target
$35.33
▲(94.33% Upside)
Technical Analysis
Adicet Bio
―
Atea Pharmaceuticals
―
Kezar Life Sciences
―
Rigel
―
Xeris Pharmaceuticals
―
Best Analysts Covering SMMT
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+191.42%
reiterated a buy rating 3 months ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +191.42% per trade.
---